Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam vs Colistin in CRE Infections
NCT05258851Phase 3Terminated
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Jun 2022
- Primary completion
- Apr 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ceftazidime + avibactam in Enterobacteriaceae infection (2 arms), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoint: 28-day Mortality. Started Jun 2022; status: terminated.
02
Drugs
ceftazidime + avibactam
03
Conditions
Enterobacteriaceae infection
Beyond the preview
Go deeper on NCT05258851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258851.